GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the ...
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday at p1,341.00. Pick the ...
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
FOR IMMEDIATE RELEASERelation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback